Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Appili Therapeutics logo — Tackling the Serious Global Challenges in Infectious Disease...

Appili Therapeutics

Tackling the Serious Global Challenges in Infectious Disease $APLI

Founded 2015 Canada Canada 19 employees Post-IPO Debt Total: $61.87M Biotechnology, Health Care +1

General Information

Company Name Appili Therapeutics
Founded Year 2015
Location Canada Canada
Employees 19
Industries Biotechnology, Health Care, Health and Wellness
Funding Stage Post-IPO Debt
Social

BounceWatch is an independent company data service, not affiliated with Appili Therapeutics. To contact Appili Therapeutics, visit appilitherapeutics.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Appili Therapeutics compare?

A PDF of Appili Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Appili Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Appili Therapeutics

Appili Therapeutics is an infectious disease biopharmaceutical company founded in 2015 in Canada. The company's slogan "Tackling the Serious Global Challenges in Infectious Disease" underscores its commitment to addressing urgent infections with unmet needs. Appili Therapeutics is driven by its mission to develop a portfolio of novel therapies aimed at preventing deaths and improving lives. Through a $300.00K Post-IPO Debt investment received on 26 April 2024 from Bloom Burton & Co., Appili Therapeutics has demonstrated its ability to attract financial support from reputable investors. As a purpose-built, portfolio-driven, and people-focused company, Appili Therapeutics is strategically positioned to combat life-threatening infections and make a meaningful impact in the Biotechnology and Health Care industries. With its clear focus and recent financial backing, Appili Therapeutics has the potential to become a major player in the infectious disease treatment space.

Business keywords: infectious disease, biopharmaceutical, portfolio-driven, pipeline development, novel therapies, urgent infections, unmet medical needs, life-threatening infections, biotech, pharmaceutical

Funding Rounds & Investors (15)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Debt $400.00K 1
Bloom Burton & Co.
Bloom Burton & Co.
26 Apr 2024
Post IPO Debt $300.00K 1
Bloom Burton & Co.
Bloom Burton & Co.
29 Jun 2023
Post IPO Debt $2.50M 1
Long Zone Holdings
20 Mar 2023
Post IPO Equity $7.00M -
13 Oct 2021
Post IPO Debt $3.50M 1
The Lind Partners, LLC
The Lind Partners, LLC
09 Aug 2021
Post IPO Equity $17.00M 5
Bloom Burton & Co. Mackie Research Capital Corporation
Bloom Burton & Co., Mackie Research Capital Corporation +3
10 Jun 2020
Post IPO Equity $10.25M -
20 Feb 2020
Debt Financing $476.00K 1
Atlantic Canada Opportunities Agency
Atlantic Canada Opportunities Agency
15 Apr 2019
Venture Round $3.60M -
26 Mar 2019
Seed Round $4.33M 1
Innovacorp
Innovacorp
07 Feb 2018

View All 15 Funding Rounds

Appili Therapeutics Alternatives & Competitors

View All Alternatives
Appili Therapeutics vs
Entero Therapeutics (Nasdaq: ENTO)
Entero Therapeutics (Nasdaq: ENTO) United States

A biopharma company focused on the development of targeted, non-systemic therapies for gastrointesti...

Post-IPO Equity
12 employees
Biotechnology, Health Care
Appili Therapeutics vs
Clarametyx Biosciences
Clarametyx Biosciences United States

Targeting biofilms to treat chronic respiratory disease

Series A
23 employees
Biotechnology, Health Care
Appili Therapeutics vs
Atea Pharmaceuticals, Inc
Atea Pharmaceuticals, Inc United States

Discovery & development of breakthrough therapies for COVID-19 patients and severe viral diseases

IPO
58 employees
Biopharma, Biotechnology
View all alternatives

FAQ About Appili Therapeutics

Tackling the Serious Global Challenges in Infectious Disease $APLI
Appili Therapeutics was founded in 2015.
Appili Therapeutics is headquartered in Canada.
Appili Therapeutics operates in Biotechnology, Health Care and Health and Wellness. Its work centres on infectious disease, biopharmaceutical, portfolio-driven and pipeline development.
Appili Therapeutics has approximately 19 employees.
Appili Therapeutics has completed 15 funding rounds, raising a total of $61.87M. The latest funding stage is Post-IPO Debt.
Top alternatives and competitors to Appili Therapeutics include Entero Therapeutics (Nasdaq: ENTO), Clarametyx Biosciences, Atea Pharmaceuticals, Inc, Newron Pharmaceuticals SpA, Dermavant Sciences, an Organon company. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Appili Therapeutics and Entero Therapeutics (Nasdaq: ENTO) are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Appili Therapeutics, https://bouncewatch.com/company/appili-therapeutics, updated 24 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout